|
Company:
|
PACIRA BIOSCIENCES, INC. (PCRX)
|
|
Form Type:
|
4
|
|
Filing Date:
|
8/16/2019
|
|
CIK:
|
0001396814
|
|
Address:
|
5 SYLVAN WAY
SUITE 300
|
|
City, State, Zip:
|
PARSIPPANY, New Jersey 07054
|
|
Telephone:
|
973-254-3560
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$43.13
|
Change:
0.21 (0.49%)
|
Trade Time:
01:50 PM EST
|
Market Cap:
$1.80B
|
|
|
|
|
|
|
Description of Business
|
|
Pacira Pharmaceuticals, Inc., a Delaware corporation, is the holding company for
our California operating subsidiary of the same name, or Pacira California. In
March 2007, we acquired Pacira California from SkyePharma Holdings, Inc. (now a
subsidiary of Vectura Group plc), or Skyepharma (referred to in this Annual
Report on Form 10-K as the "Skyepharma Acquisition"). Unless the context
requires otherwise, references to "Pacira," "we," the "Company," "us" and "our"
in this Annual Report on Form 10-K refers to Pacira Pharmaceuticals, Inc., a
Delaware corporation, and its subsidiaries.
Corporate Information
We were incorporated in Delaware under the name Blue Acquisition Corp. in
December 2006 and changed our name to Pacira, Inc. in June 2007. In October
2010, we changed our name to Pacira Pharmaceuticals, Inc. Our principal
executive offices are in Parsippany, New Jersey.
Pacira®, EXPAREL®, DepoFoam®, DepoCyt® (United States (U.S.
|
|
|
|